Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
ASX
Unprofitable
EPS improving
Unprofitable
EPS improving
309M
Biotechnology
Next Earning date - 28 Aug 2025
309M
Biotechnology
Next Earning date - 28 Aug 2025
Relative Strenght
Volume Buzz
-61%Earning Acce
YesDist 52w H.
29%